Intrinsic Value

The intrinsic value of Privia Health Group Inc (PRVA) under the Base Case is 26.2 USD per share. Compared with the current market price of 24.37 USD, the stock appears Undervalued by 7% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

PRVA Intrinsic Value
$26.2
Undervaluation 7%
Intrinsic Value
Price $24.37

PRVA is cheaper than usual. It was this cheap or cheaper on just 19% of days in the past 5 years.

Monitor PRVA
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $20.96
Get notified when the price drops into your buy zone
Intrinsic Value $26.2
Current Price $24.37
Margin of Safety 20% $20.96
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to PRVA

Fundamental Analysis

What Privia Health Group Does

Health Care

Privia Health Group helps doctors and medical practices run more efficiently without giving up their independence. It builds a network of primary care and specialty physicians, gives them software and administrative support, and helps them manage patient care, billing, scheduling, and quality reporting. Its main customers are independent physicians and practice groups that want the scale of a larger organization while staying separate from a hospital system.

Headquarters
United States of America US
Employees
1 226
IPO date
Apr 29, 2021
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Privia Health Group Inc

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

PRVA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PRVA stock?

The intrinsic value for Privia Health Group Inc (PRVA) under the Base Case is 26.2 USD.

Is PRVA stock undervalued or overvalued?

Compared with the current market price of 24.37 USD, the stock appears Undervalued by 7% .

Back to Top